JP2004506684A - 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法 - Google Patents

肝細胞への薬物送達及びフラビウイルス感染症の治療の方法 Download PDF

Info

Publication number
JP2004506684A
JP2004506684A JP2002520825A JP2002520825A JP2004506684A JP 2004506684 A JP2004506684 A JP 2004506684A JP 2002520825 A JP2002520825 A JP 2002520825A JP 2002520825 A JP2002520825 A JP 2002520825A JP 2004506684 A JP2004506684 A JP 2004506684A
Authority
JP
Japan
Prior art keywords
compound
hepatocytes
virus
carboxamidine
transporter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002520825A
Other languages
English (en)
Japanese (ja)
Inventor
ラウ，ジヨンソン
ホン，チー
Original Assignee
リバフアーム・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リバフアーム・インコーポレーテツド filed Critical リバフアーム・インコーポレーテツド
Publication of JP2004506684A publication Critical patent/JP2004506684A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2002520825A 2000-08-22 2001-08-21 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法 Withdrawn JP2004506684A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22686900P 2000-08-22 2000-08-22
US24062700P 2000-10-13 2000-10-13
PCT/US2001/026057 WO2002015904A1 (en) 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Publications (1)

Publication Number Publication Date
JP2004506684A true JP2004506684A (ja) 2004-03-04

Family

ID=26920944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002520825A Withdrawn JP2004506684A (ja) 2000-08-22 2001-08-21 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法

Country Status (15)

Country Link
EP (1) EP1313469A1 (zh)
JP (1) JP2004506684A (zh)
KR (1) KR20030040416A (zh)
CN (1) CN1447692A (zh)
AU (1) AU2001292557A1 (zh)
BR (1) BR0113388A (zh)
CA (1) CA2415793A1 (zh)
CZ (1) CZ2003308A3 (zh)
HU (1) HUP0302884A2 (zh)
IL (1) IL154167A0 (zh)
MX (1) MXPA03001529A (zh)
NO (1) NO20030794L (zh)
PL (1) PL365744A1 (zh)
RU (1) RU2003102607A (zh)
WO (1) WO2002015904A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
US20100112081A1 (en) 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5959077A (en) * 1993-05-26 1999-09-28 Laboratori Balducci S.P.A. Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2415793A1 (en) 2002-02-28
NO20030794L (no) 2003-04-22
WO2002015904B1 (en) 2002-07-04
CN1447692A (zh) 2003-10-08
BR0113388A (pt) 2004-02-25
IL154167A0 (en) 2003-07-31
NO20030794D0 (no) 2003-02-20
CZ2003308A3 (cs) 2004-03-17
WO2002015904A1 (en) 2002-02-28
HUP0302884A2 (hu) 2003-12-29
AU2001292557A1 (en) 2002-03-04
EP1313469A1 (en) 2003-05-28
KR20030040416A (ko) 2003-05-22
PL365744A1 (en) 2005-01-10
MXPA03001529A (es) 2004-04-02
RU2003102607A (ru) 2004-07-27

Similar Documents

Publication Publication Date Title
CA2445744C (en) Antiviral nucleoside derivatives
US6495677B1 (en) Nucleoside compounds
CN100490818C (zh) β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
US6232298B1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
CA2223640A1 (en) Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated pyrimidine nucleosides
JP2008007525A (ja) 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
US6423695B1 (en) Cytokine related treatments of disease
JP2007332144A (ja) 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体
JPH06508846A (ja) アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療
JP2004506684A (ja) 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法
CN1312254A (zh) 新的核苷
US20040077563A1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
US6329350B1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
ZA200300649B (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections.
Curran et al. Clofarabine: in pediatric patients with acute lymphoblastic leukemia
AU2005232286A1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AU2004201154A1 (en) Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Hepatitis
AU5262499A (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070525